Novartis AG (BCBA:NVS)
Argentina · Delayed Price · Currency is ARS 39,300
+550 (1.42%)
Last updated: Aug 1, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 46.35% | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines | 50.32B | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines Growth | 12.85% | Log In | Log In | Log In | Log In | Upgrade |
Sandoz | - | Log In | Log In | Log In | Log In | Upgrade |
Sandoz Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular, Renal And Metabolic | 8.58B | Log In | Log In | Log In | Log In | Upgrade |
Cardiovascular, Renal And Metabolic Growth | 29.50% | Log In | Log In | Log In | Log In | Upgrade |
Immunology | 9.29B | Log In | Log In | Log In | Log In | Upgrade |
Immunology Growth | 15.98% | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience | 4.75B | Log In | Log In | Log In | Log In | Upgrade |
Neuroscience Growth | 23.76% | Log In | Log In | Log In | Log In | Upgrade |
Oncology | 14.74B | Log In | Log In | Log In | Log In | Upgrade |
Oncology Growth | 19.24% | Log In | Log In | Log In | Log In | Upgrade |
Established Brands | 12.96B | Log In | Log In | Log In | Log In | Upgrade |
Established Brands Growth | -10.19% | Log In | Log In | Log In | Log In | Upgrade |
Other | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 46.35% | Log In | Log In | Log In | Log In | Upgrade |
Other | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 46.35% | Log In | Log In | Log In | Log In | Upgrade |
Other | 1.41B | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | 46.35% | Log In | Log In | Log In | Log In | Upgrade |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines Operating Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Sandoz Operating Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Sandoz Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Operating Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Operating Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Gross Income by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines Gross Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Innovative Medicines Gross Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Sandoz Gross Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Sandoz Gross Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Gross Profit | - | Log In | Log In | Log In | Log In | Upgrade |
Corporate Gross Profit Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States Revenue (Post-Q2 2023 Reporting) | 21.15B | Log In | Log In | Log In | Log In | Upgrade |
United States Revenue (Post-Q2 2023 Reporting) Growth | 22.08% | Log In | Log In | Log In | Log In | Upgrade |
Europe Revenue (Post-Q2 2023 Reporting) | 15.56B | Log In | Log In | Log In | Log In | Upgrade |
Europe Revenue (Post-Q2 2023 Reporting) Growth | 4.74% | Log In | Log In | Log In | Log In | Upgrade |
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) | 10.02B | Log In | Log In | Log In | Log In | Upgrade |
Asia/Africa/Australasia Revenue (Post-Q2 2023 Reporting) Growth | 5.93% | Log In | Log In | Log In | Log In | Upgrade |
Canada and Latin America Revenue (Post-Q2 2023 Reporting) | 3.59B | Log In | Log In | Log In | Log In | Upgrade |
Canada and Latin America Revenue (Post-Q2 2023 Reporting) Growth | 5.55% | Log In | Log In | Log In | Log In | Upgrade |
Other | - | Log In | Log In | Log In | Log In | Upgrade |
Other Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Europe Revenue (Pre-Q3 2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Europe Revenue (Pre-Q3 2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
United States Revenue (Pre-Q3 2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
United States Revenue (Pre-Q3 2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Asia/Africa/Australasia Revenue (Pre-Q3 2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Canada and Latin America Revenue (Pre-Q3 2023 Reporting) | - | Log In | Log In | Log In | Log In | Upgrade |
Canada and Latin America Revenue (Pre-Q3 2023 Reporting) Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
Gilenya Revenue | 552.00M | Log In | Log In | Log In | Log In | Upgrade |
Gilenya Revenue Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Tasigna Revenue | 1.67B | Log In | Log In | Log In | Log In | Upgrade |
Tasigna Revenue Growth | -12.39% | Log In | Log In | Log In | Log In | Upgrade |
Lucentis Revenue | 1.04B | Log In | Log In | Log In | Log In | Upgrade |
Lucentis Revenue Growth | -34.80% | Log In | Log In | Log In | Log In | Upgrade |
Cosentyx Revenue | 6.14B | Log In | Log In | Log In | Log In | Upgrade |
Cosentyx Revenue Growth | 17.65% | Log In | Log In | Log In | Log In | Upgrade |
Entresto Revenue | 7.82B | Log In | Log In | Log In | Log In | Upgrade |
Entresto Revenue Growth | 25.61% | Log In | Log In | Log In | Log In | Upgrade |